Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Published:2009-07 Issue:2 Volume:146 Page:164-170
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Chen Christine,Reece Donna E.,Siegel David,Niesvizky Ruben,Boccia Ralph V.,Stadtmauer Edward A.,Abonour Rafat,Richardson Paul,Matous Jeffrey,Kumar Shaji,Bahlis Nizar J.,Alsina Melissa,Vescio Robert,Coutre Steven E.,Pietronigro Dennis,Knight Robert D.,Zeldis Jerome B.,Rajkumar Vincent

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07728.x/fullpdf

Reference24 articles.

1. Multiple myeloma. Clinical practice guidelines in oncology;Anderson;Journal of the National Comprehensive Cancer Network,2007

2. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients;Barlogie;Blood,2001

3. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma;Baz;Mayo Clinic Proceedings,2005

4. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha;Corral;Journal of Immunology,1999

5. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;New England Journal of Medicine,2007

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced practice nurse management in multiple myeloma treated with oral therapy;Bulletin du Cancer;2023-12

2. Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target-specific Nanotherapies in Disease Models;Current Drug Therapy;2022-10

3. Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations;Frontiers in Pharmacology;2022-05-23

4. Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium;Clinical Lymphoma Myeloma and Leukemia;2022-01

5. Oral Therapies for Multiple Myeloma;Oncology & Haematology;2022